ClinicalTrials.gg

Program

GKL-006

A development code. Also written as “GKL-006 Injection” and “GKL-006 injection”.

Its studies are mostly in Carcinoma, Hepatocellular · Pancreatic Neoplasms, led by Beijing Gene Key Life Technology.

Furthest: phase 2, since Sep 29, 20254 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Gene Key Life Technology43 open or runningphase 2since Sep 29, 2025Sep 29, 2025Mar 31, 2027phase 2 · NCT07777211

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT07209813 · 48 planned · China
  2. Jun 12, 2026Phase 1 study in Carcinoma, HepatocellularNCT07713290 · 6 enrolled · China
  3. Aug 17, 2026Phase 2 study in Advanced Pancreatic CancerNCT07777211 · 52 planned · China
  4. Sep 22, 2026Phase 1 study in Carcinoma, HepatocellularNCT07845266 · 13 enrolled · China

Ahead

  1. Nov 12, 2026Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07713290
  2. Mar 31, 2027Primary completion: phase 2 study in Advanced Pancreatic CancerNCT07777211
  3. Sep 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07209813

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07845266Carcinoma, Hepatocellular · China1CompletedApr 9, 202513
NCT07777211Advanced Pancreatic Cancer · China2RecruitingMar 31, 202752
NCT07713290Carcinoma, Hepatocellular · China1Active, not recruitingNov 12, 20266
NCT07209813Carcinoma, Hepatocellular · China2RecruitingSep 30, 202748

How it is read

Names in the registry

  • “GKL-006 Injection”, 3 entries
  • “GKL-006 injection”, 1 entry

Codes read as this program: GKL006.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.